Area of research
Public Health, Environmental and Occupational Health · Hematology
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Chronic Lymphocytic Leukemia Research, and Chronic Myeloid Leukemia Treatments.
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.
Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.
Reply to: Accurate Determinants of Outcome in ALL.
Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia.
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL.
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children's Oncology Group report.
Table S5 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S4 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S3 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Data from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Table S9 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S4 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S10 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S7 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S7 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S2 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Data from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S8 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S9 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S5 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Supplementary Data 1 from CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells
Table S6 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S8 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Supplementary Figures S1-S11 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia
Table S3 from Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia